The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers

Cancer Cell

Volumn 28, Issue 4, 2015, Pages 515-528

  Han, Leng ^a   Diao, Lixia ^a   Yu, Shuangxing ^a   Xu, Xiaoyan ^a,b   Li, Jie ^a   Zhang, Rui ^c,g   Yang, Yang ^a,d   Werner, Henrica M J ^a,e   Eterovic, A Karina ^a   Yuan, Yuan ^a   Li, Jun ^a   Nair, Nikitha ^f   Minelli, Rosalba ^f   Tsang, Yiu Huen ^f   Cheung, Lydia W T ^a   Jeong, Kang Jin ^a   Roszik, Jason ^a   Ju, Zhenlin ^a   Woodman, Scott E ^a   Lu, Yiling ^a   Scott, Kenneth L ^f   Li, Jin Billy ^c   Mills, Gordon B ^a   Liang, Han ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CHINA MEDICAL UNIVERSITY   (China)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; INOSINE; UNTRANSLATED RNA; ANTINEOPLASTIC AGENT;

ARTICLE; BREAST INVASIVE CARCINOMA; CANCER STAGING; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CELL VIABILITY ASSAY; DNA BASE COMPOSITION; GENETIC VARIABILITY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN GENOME; HUMAN TISSUE; INVASIVE CARCINOMA; LIVER CANCER; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; OVERALL SURVIVAL; PRIORITY JOURNAL; RNA EDITING; RNA SEQUENCE; SOMATIC MUTATION; THYROID CARCINOMA; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

ADENOSINE; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; GENOME, HUMAN; HUMANS; INOSINE; NEOPLASMS; RNA EDITING;

EID: 84944062619     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.08.013     Document Type: Article

References (51)

1. Bahn J.H., Lee J.H., Li G., Greer C., Peng G., Xiao X. Accurate identification of A-to-I RNA editing in human by transcriptome sequencing. Genome Res. 2012, 22:142-150.
2. Barretina J., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity (vol 483, pg 603, 2012). Nature 2012, 492. 290-290.
3. Bass B.L. RNA editing by adenosine deaminases that act on RNA. Annu. Rev. Biochem. 2002, 71:817-846.
4. Bass B.L., Nishikura K., Keller W., Seeburg P.H., Emeson R.B., O'Connell M.A., Samuel C.E., Herbert A. A standardized nomenclature for adenosine deaminases that act on RNA. RNA 1997, 3:947-949.
5. Bazak L., Haviv A., Barak M., Jacob-Hirsch J., Deng P., Zhang R., Isaacs F.J., Rechavi G., Li J.B., Eisenberg E., Levanon E.Y. A-to-I RNA editing occurs at over a hundred million genomic sites, located in a majority of human genes. Genome Res. 2014, 24:365-376.
6. Brennan C.W., Verhaak R.G.W., McKenna A., Campos B., Noushmehr H., Salama S.R., Zheng S., Chakravarty D., Sanborn J.Z., Berman S.H., et al. The somatic genomic landscape of glioblastoma. Cell 2013, 155:462-477. TCGA Research Network.
7. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337. Cancer Genome Atlas Network.
8. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. Cancer Genome Atlas Network.
9. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068. Cancer Genome Atlas Research Network.
10. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489:519-525. Cancer Genome Atlas Research Network.
11. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013, 499:43-49. Cancer Genome Atlas Research Network.
12. Carter S.L., Cibulskis K., Helman E., McKenna A., Shen H., Zack T., Laird P.W., Onofrio R.C., Winckler W., Weir B.A., et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 2012, 30:413-421.
13. Cenci C., Barzotti R., Galeano F., Corbelli S., Rota R., Massimi L., Di Rocco C., O'Connell M.A., Gallo A. Down-regulation of RNA editing in pediatric astrocytomas: ADAR2 editing activity inhibits cell migration and proliferation. J. Biol. Chem. 2008, 283:7251-7260.
14. Chan T.H., Lin C.H., Qi L., Fei J., Li Y., Yong K.J., Liu M., Song Y., Chow R.K., Ng V.H., et al. A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. Gut 2014, 63:832-843.
15. Chen C.X., Cho D.S.C., Wang Q., Lai F., Carter K.C., Nishikura K. A third member of the RNA-specific adenosine deaminase gene family, ADAR3, contains both single- and double-stranded RNA binding domains. RNA 2000, 6:755-767.
16. Chen L., Li Y., Lin C.H., Chan T.H.M., Chow R.K.K., Song Y., Liu M., Yuan Y.F., Fu L., Kong K.L., et al. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat. Med. 2013, 19:209-216.
17. Cheung L.W., Yu S., Zhang D., Li J., Ng P.K., Panupinthu N., Mitra S., Ju Z., Yu Q., Liang H., et al. Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors. Cancer Cell 2014, 26:479-494.
18. Chilibeck K.A., Wu T., Liang C., Schellenberg M.J., Gesner E.M., Lynch J.M., MacMillan A.M. FRET analysis of in vivo dimerization by RNA-editing enzymes. J. Biol. Chem. 2006, 281:16530-16535.
19. Fumagalli D., Gacquer D., Rothé F., Lefort A., Libert F., Brown D., Kheddoumi N., Shlien A., Konopka T., Salgado R., et al. Principles governing A-to-I RNA editing in the breast cancer transcriptome. Cell Rep. 2015, 13. Published online October 1, 2015. 10.1016/j.celrep.2015.09.032.
20. Cho D.S., Yang W., Lee J.T., Shiekhattar R., Murray J.M., Nishikura K. Requirement of dimerization for RNA editing activity of adenosine deaminases acting on RNA. J. Biol. Chem. 2003, 278:17093-17102.
21. Galeano F., Rossetti C., Tomaselli S., Cifaldi L., Lezzerini M., Pezzullo M., Boldrini R., Massimi L., Di Rocco C.M., Locatelli F., Gallo A. ADAR2-editing activity inhibits glioblastoma growth through the modulation of the CDC14B/Skp2/p21/p27 axis. Oncogene 2013, 32:998-1009.
22. Gu T., Buaas F.W., Simons A.K., Ackert-Bicknell C.L., Braun R.E., Hibbs M.A. Canonical A-to-I and C-to-U RNA editing is enriched at 3'UTRs and microRNA target sites in multiple mouse tissues. PLoS ONE 2012, 7:e33720.
23. Han S.W., Kim H.P., Shin J.Y., Jeong E.G., Lee W.C., Kim K.Y., Park S.Y., Lee D.W., Won J.K., Jeong S.Y., et al. RNA editing in RHOQ promotes invasion potential in colorectal cancer. J. Exp. Med. 2014, 211:613-621.
24. Herb A., Higuchi M., Sprengel R., Seeburg P.H. Q/R site editing in kainate receptor GluR5 and GluR6 pre-mRNAs requires distant intronic sequences. Proc. Natl. Acad. Sci. U S A 1996, 93:1875-1880.
25. Higuchi M., Single F.N., Köhler M., Sommer B., Sprengel R., Seeburg P.H. RNA editing of AMPA receptor subunit GluR-B: a base-paired intron-exon structure determines position and efficiency. Cell 1993, 75:1361-1370.
26. Jiang Q., Crews L.A., Barrett C.L., Chun H.J., Court A.C., Isquith J.M., Zipeto M.A., Goff D.J., Minden M., Sadarangani A., et al. ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia. Proc. Natl. Acad. Sci. U S A 2013, 110:1041-1046.
27. Kandoth C., Schultz N., Cherniack A.D., Akbani R., Liu Y., Shen H., Robertson A.G., Pashtan I., Shen R., Benz C.C., et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013, 497:67-73. Cancer Genome Atlas Research Network.
28. Kawahara Y., Zinshteyn B., Sethupathy P., Iizasa H., Hatzigeorgiou A.G., Nishikura K. Redirection of silencing targets by adenosine-to-inosine editing of miRNAs. Science 2007, 315:1137-1140.
29. Keegan L.P., Gallo A., O'Connell M.A. The many roles of an RNA. Nat. Rev. Genet. 2001, 2:869-878.
30. Li M., Wang I.X., Li Y., Bruzel A., Richards A.L., Toung J.M., Cheung V.G. Widespread RNA and DNA sequence differences in the human transcriptome. Science 2011, 333:53-58.
31. Liang H., Landweber L.F. Hypothesis: RNA editing of microRNA target sites in humans?. RNA 2007, 13:463-467.
32. Liang H., Cheung L.W.T., Li J., Ju Z., Yu S., Stemke-Hale K., Dogruluk T., Lu Y., Liu X., Gu C., et al. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res. 2012, 22:2120-2129.
33. Maas S., Rich A. Changing genetic information through RNA editing. BioEssays 2000, 22:790-802.
34. Maas S., Patt S., Schrey M., Rich A. Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc. Natl. Acad. Sci. U S A 2001, 98:14687-14692.
35. Martinez H.D., Jasavala R.J., Hinkson I., Fitzgerald L.D., Trimmer J.S., Kung H.J., Wright M.E. RNA editing of androgen receptor gene transcripts in prostate cancer cells. J. Biol. Chem. 2008, 283:29938-29949.
36. Nemlich Y., Greenberg E., Ortenberg R., Besser M.J., Barshack I., Jacob-Hirsch J., Jacoby E., Eyal E., Rivkin L., Prieto V.G., et al. MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. J. Clin. Invest. 2013, 123:2703-2718.
37. Omberg L., Ellrott K., Yuan Y., Kandoth C., Wong C., Kellen M.R., Friend S.H., Stuart J., Liang H., Margolin A.A. Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas. Nat. Genet. 2013, 45:1121-1126.
38. Paz N., Levanon E.Y., Amariglio N., Heimberger A.B., Ram Z., Constantini S., Barbash Z.S., Adamsky K., Safran M., Hirschberg A., et al. Altered adenosine-to-inosine RNA editing in human cancer. Genome Res. 2007, 17:1586-1595.
39. Paz-Yaacov N., Bazak L., Buchumenski I., Porath H.T., Danan-Gotthold M., Knisbacher B.A., Eisenberg E., Levanon E.Y. Elevated RNA editing activity is a major contributor to transcriptomic diversity in tumors. Cell Rep. 2015, 13. Published online October 1, 2015. 10.1016/j.celrep.2015.08.080.
40. Peng Z., Cheng Y., Tan B.C.M., Kang L., Tian Z., Zhu Y., Zhang W., Liang Y., Hu X., Tan X., et al. Comprehensive analysis of RNA-Seq data reveals extensive RNA editing in a human transcriptome. Nat. Biotechnol. 2012, 30:253-260.
41. Piskol R., Peng Z., Wang J., Li J.B. Lack of evidence for existence of noncanonical RNA editing. Nat. Biotechnol. 2013, 31:19-20.
42. Qin Y.R., Qiao J.J., Chan T.H., Zhu Y.H., Li F.F., Liu H., Fei J., Li Y., Guan X.Y., Chen L. Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma. Cancer Res. 2014, 74:840-851.
43. Quayle S.N., Lee J.Y., Cheung L.W., Ding L., Wiedemeyer R., Dewan R.W., Huang-Hobbs E., Zhuang L., Wilson R.K., Ligon K.L., et al. Somatic mutations of PIK3R1 promote gliomagenesis. PLoS ONE 2012, 7:e49466.
44. Ramaswami G., Li J.B. RADAR: a rigorously annotated database of A-to-I RNA editing. Nucleic Acids Res. 2014, 42:D109-D113.
45. Ramaswami G., Lin W., Piskol R., Tan M.H., Davis C., Li J.B. Accurate identification of human Alu and non-Alu RNA editing sites. Nat. Methods 2012, 9:579-581.
46. Ramaswami G., Zhang R., Piskol R., Keegan L.P., Deng P., O'Connell M.A., Li J.B. Identifying RNA editing sites using RNA sequencing data alone. Nat. Methods 2013, 10:128-132.
47. Rueter S.M., Dawson T.R., Emeson R.B. Regulation of alternative splicing by RNA editing. Nature 1999, 399:75-80.
48. Tomaselli S., Galeano F., Alon S., Raho S., Galardi S., Polito V.A., Presutti C., Vincenti S., Eisenberg E., Locatelli F., Gallo A. Modulation of microRNA editing, expression and processing by ADAR2 deaminase in glioblastoma. Genome Biol. 2015, 16:5.
49. Wahlstedt H., Daniel C., Ensterö M., Ohman M. Large-scale mRNA sequencing determines global regulation of RNA editing during brain development. Genome Res. 2009, 19:978-986.
50. Wang K., Li M., Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010, 38:e164.
51. Weinstein J.N., Collisson E.A., Mills G.B., Shaw K.R., Ozenberger B.A., Ellrott K., Shmulevich I., Sander C., Stuart J.M. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 2013, 45:1113-1120. Cancer Genome Atlas Research Network.